The Role of hCG in Thawed Embryo Transfer

Fertility Center of Las Vegas (FCLV)

Status and phase: Enrolling; Phase 4

Conditions: Infertility (IVF Patients)

Treatments: Other: No intervention; Drug: HCG injection

Study type: Interventional

Funder types: Industry

Identifiers

NCT07004192

FCLV 2025-1

Details and patient eligibility

About

This prospective randomized trial will assess the relevance, if any, of a corpus luteum induced by hCG in transfers of thawed embryos.

Full description

The current study is designed to carefully isolate the effect of a corpus luteum by ensuring that the presence or absence of a corpus luteum is the only difference between two study arms. This should be reliably achieved by administering an injection of hCG in one study arm, while the other study arm has identical treatment except for omitting the hCG.

Enrollment: 220 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Female adult expecting to receive transfer of a thawed embryo.
2. At least one available frozen blastocyst of transferrable quality.
3. Non-menopausal female with at least one antral follicle.
4. Use of pre-implantation genetic testing (PGT), embryos derived from donor oocytes and/or donor sperm, a gestational carrier, and history of prior transfer(s) regardless of outcome are allowed.
5. Subsequent embryo transfers after failed transfers under this study are allowed, but not after a transfer that has resulted in ongoing pregnancy at ten weeks gestation under this study.

Exclusion criteria

1. Minors (age<18 years).
2. Use of embryo(s) frozen at another center.
3. Patient insistent on transfer of two embryos.
4. Patient or partner unable to provide informed consent in English.
5. Patient already enrolled in any other research study for her embryo transfer.
6. History of anti-phospholipid syndrome or any other indication for use of Lovenox in pregnancy.
7. Patient for whom the physician assesses this protocol is inappropriate or unsafe.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

220 participants in 2 patient groups

hCG Group

Experimental group

Description:

This group receives one injection of hCG.

Treatment:

Drug: HCG injection

No hCG Group

Active Comparator group

Description:

This arm receives no hCG.

Treatment:

Other: No intervention